1Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2Department of Surgery, Keio ...

Additionally, targeting the SDF1/CXCR4 axis represents an exciting avenue for therapeutic intervention. Several CXCR4 inhibitors, such as plerixafor (AMD3100) and BL-8040, have shown promise in ...